{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-025762","form_type":"8-K","ticker":"WINT","cik":"0000946486","company_name":"WINDTREE THERAPEUTICS INC /DE/","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.752385+00:00","generated_at":"2026-05-17T16:56:37.551573+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Windtree terminates SEISMiC-C study of istaroxime after 20 enrollments; cites limited resources","bullets":["Terminated Phase 2 SEISMiC-C trial (istaxime for cardiogenic SCAI Stage C) at 20 enrollments.","Decision driven by limited resources and desire to advance istaroxime into broader acute heart failure.","No safety concerns were cited as the reason for termination.","CEO Jed Latkin confirmed the termination in the 8-K filing filed August 8, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-025762","json":"https://secwatch.observer/filing/0001437749-25-025762.json","markdown":"https://secwatch.observer/filing/0001437749-25-025762.md","text":"https://secwatch.observer/filing/0001437749-25-025762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946486/000143774925025762/0001437749-25-025762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946486/000143774925025762/wint20250808_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:56:37.551573+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}